Zacks Research Predicts Lower Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD) – Zacks Research decreased their FY2025 earnings per share (EPS) estimates for shares of Gilead Sciences in a report released on Tuesday, September 23rd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $7.76 per share for the year, down from their prior forecast of $7.98. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.82 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS.

Several other research firms have also commented on GILD. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Royal Bank Of Canada boosted their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a research report on Tuesday, August 19th. Finally, Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $117.17.

Gilead Sciences Trading Down 2.4%

Shares of NASDAQ GILD opened at $110.99 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The business has a fifty day simple moving average of $114.34 and a two-hundred day simple moving average of $109.96. The firm has a market cap of $137.72 billion, a PE ratio of 22.11, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. Gilead Sciences has a twelve month low of $81.83 and a twelve month high of $121.83.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer owned 595,725 shares in the company, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,000 shares of company stock worth $9,390,030. 0.27% of the stock is currently owned by insiders.

Institutional Trading of Gilead Sciences

Several large investors have recently added to or reduced their stakes in GILD. Norges Bank purchased a new stake in Gilead Sciences during the 2nd quarter valued at about $2,150,268,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Gilead Sciences in the first quarter worth about $620,415,000. Ameriprise Financial Inc. boosted its stake in shares of Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after buying an additional 5,392,191 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.